A New Organoid Model Illuminates the Molecular Roots of Epilepsy
A groundbreaking study published in *Brain* leverages patient-derived human cortical organoids to model focal cortical dysplasia type II (FCDII), a leading cause of drug-resistant pediatric epilepsy. Researchers created a mosaic model with biallelic inactivation of the *DEPDC5* gene, a key mTOR pathway repressor. This model successfully recapitulated core disease hallmarks, including hyperactive mTOR signaling, dysmorphic neurons, and increased neuronal excitability—all of which were normalized by the mTOR inhibitor rapamycin. Advanced single-cell transcriptomic analysis across developmental stages revealed profound disruptions, including premature neuron differentiation, altered synaptic gene expression, and cell-autonomous metabolic changes, providing an unprecedented window into the developmental origins of this severe neurological disorder.
Study Significance: This research represents a significant advance in molecular diagnostics for neurological disease, demonstrating how sophisticated *in vitro* models can decode complex genetic pathologies. For laboratory medicine, it underscores the growing importance of integrating functional genomic data from models like organoids with traditional diagnostic testing to understand disease mechanisms. The findings highlight potential new biomarkers within the mTOR and associated signaling pathways, which could eventually inform more targeted therapeutic drug monitoring strategies for patients with mTORopathies.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
